PL4255406T3 - Kwas (2s)-2-aminopentanotiowy do zastosowania jako lek oraz w terapii stwardnienia zanikowego bocznego - Google Patents
Kwas (2s)-2-aminopentanotiowy do zastosowania jako lek oraz w terapii stwardnienia zanikowego bocznegoInfo
- Publication number
- PL4255406T3 PL4255406T3 PL20900746.7T PL20900746T PL4255406T3 PL 4255406 T3 PL4255406 T3 PL 4255406T3 PL 20900746 T PL20900746 T PL 20900746T PL 4255406 T3 PL4255406 T3 PL 4255406T3
- Authority
- PL
- Poland
- Prior art keywords
- aminopentanethioic
- medicament
- therapy
- acid
- lateral sclerosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/RU2020/000661 WO2022119470A1 (en) | 2020-12-04 | 2020-12-04 | (2s)-2-aminopentanethioic s-acid for use as medicament and in therapy of amyotrophic lateral sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4255406T3 true PL4255406T3 (pl) | 2026-05-04 |
Family
ID=76444523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20900746.7T PL4255406T3 (pl) | 2020-12-04 | 2020-12-04 | Kwas (2s)-2-aminopentanotiowy do zastosowania jako lek oraz w terapii stwardnienia zanikowego bocznego |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12533330B2 (pl) |
| EP (1) | EP4255406B1 (pl) |
| CN (1) | CN117320703A (pl) |
| AU (1) | AU2020480023A1 (pl) |
| CA (1) | CA3207232A1 (pl) |
| ES (1) | ES3066377T3 (pl) |
| HR (1) | HRP20260394T1 (pl) |
| PL (1) | PL4255406T3 (pl) |
| WO (1) | WO2022119470A1 (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117320703A (zh) | 2020-12-04 | 2023-12-29 | 马西创投有限公司 | 用作药物并用于治疗肌萎缩侧索硬化症的(2s)-2-氨基硫代s戊酸 |
| WO2026049634A1 (en) * | 2024-08-26 | 2026-03-05 | Massey Ventures Limited | (2s)-2-aminopentanethioic s-acid for use in the therapy of diabetes mellitus or complications thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1576886A (en) * | 1977-04-20 | 1980-10-15 | Lepetit Spa | Rifamycin derivatives |
| CA3078006C (en) * | 2012-07-10 | 2022-04-26 | Xpd Holdings, Llc | Stabilized multi-functional antioxidant compounds and methods of use |
| CN117320703A (zh) | 2020-12-04 | 2023-12-29 | 马西创投有限公司 | 用作药物并用于治疗肌萎缩侧索硬化症的(2s)-2-氨基硫代s戊酸 |
-
2020
- 2020-12-04 CN CN202080108374.9A patent/CN117320703A/zh active Pending
- 2020-12-04 HR HRP20260394TT patent/HRP20260394T1/hr unknown
- 2020-12-04 AU AU2020480023A patent/AU2020480023A1/en active Pending
- 2020-12-04 US US18/258,514 patent/US12533330B2/en active Active
- 2020-12-04 EP EP20900746.7A patent/EP4255406B1/en active Active
- 2020-12-04 WO PCT/RU2020/000661 patent/WO2022119470A1/en not_active Ceased
- 2020-12-04 PL PL20900746.7T patent/PL4255406T3/pl unknown
- 2020-12-04 CA CA3207232A patent/CA3207232A1/en active Pending
- 2020-12-04 ES ES20900746T patent/ES3066377T3/es active Active
-
2026
- 2026-01-06 US US19/441,748 patent/US20260137640A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES3066377T3 (en) | 2026-05-12 |
| WO2022119470A1 (en) | 2022-06-09 |
| CA3207232A1 (en) | 2022-06-09 |
| US12533330B2 (en) | 2026-01-27 |
| CN117320703A (zh) | 2023-12-29 |
| AU2020480023A1 (en) | 2023-08-03 |
| EP4255406A1 (en) | 2023-10-11 |
| US20260137640A1 (en) | 2026-05-21 |
| HRP20260394T1 (hr) | 2026-05-08 |
| EP4255406C0 (en) | 2026-03-11 |
| US20240058285A1 (en) | 2024-02-22 |
| EP4255406B1 (en) | 2026-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY173215A (en) | Acetylcysteine compositions and methods of use thereof | |
| HK1198278A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta | |
| MX2014001050A (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero. | |
| GEP20166455B (en) | Methods of administering pirfenidone therapy | |
| WO2012135812A3 (en) | Treatment for dermatological pathologies | |
| PH12017501688A1 (en) | Intranasal benzodiazepine pharmaceutical compositions | |
| PH12014501560A1 (en) | Carbamate compounds and of making and using same | |
| ES3066377T3 (en) | (2s)-2-aminopentanethioic acid for use as medicament and in therapy of amyotrophic lateral sclerosis | |
| EA201590166A8 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| NZ701607A (en) | Therapeutic use of chardonnay seed products | |
| MX2010010954A (es) | Farmaco contra cancer de higado. | |
| MY175764A (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
| BR112012027092A2 (pt) | métodos e composiões para reduzir ou impedir a calcificação vascular durante a terapia de diálise peritoneal | |
| MX2015000398A (es) | Formulaciones de laquinimod sin agente alcalinizante. | |
| GB201206486D0 (en) | Vesicular formulations and uses thereof | |
| MY171526A (en) | Pharmaceutical formulation for reducing frequency of urination and method of use thereof | |
| MX2014002817A (es) | Suspension oral. | |
| MX2010011193A (es) | Composicion farmaceutica liquida para el tratamiento y prevencion del dolor. | |
| WO2012098342A8 (en) | (r)-1,2-propanediol for use as a solvent in therapeutic cooling agent compositions | |
| ZA202400915B (en) | Pharmaceutical composition and use thereof | |
| MX2016010482A (es) | Combinaciones farmaceuticas que comprenden un inhibidor de pi3k para el tratamiento de cancer. | |
| IN2015DN00966A (pl) | ||
| IN2014DN09092A (pl) | ||
| PH12012502185A1 (en) | Association of xanthine oxidase inhibitors and statins and use thereof | |
| PH12014500252A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate |